- Home
- ATXS vs REPL Comparison
ATXS vs REPL Comparison
Compare ATXS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- REPL
- Stock Information
- Founded
- ATXS 2008
- REPL 2015
- Country
- ATXS United States
- REPL United States
- Employees
- ATXS N/A
- REPL N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- ATXS Health Care
- REPL Health Care
- Exchange
- ATXS Nasdaq
- REPL Nasdaq
- Market Cap
- ATXS 676.1M
- REPL 547.0M
- IPO Year
- ATXS 2015
- REPL 2018
- Fundamental
- Price
- ATXS $12.50
- REPL $9.42
- Analyst Decision
- ATXS Hold
- REPL Buy
- Analyst Count
- ATXS 6
- REPL 9
- Target Price
- ATXS $24.33
- REPL $12.00
- AVG Volume (30 Days)
- ATXS 936.9K
- REPL 2.6M
- Earning Date
- ATXS 11-12-2025
- REPL 11-06-2025
- Dividend Yield
- ATXS N/A
- REPL N/A
- EPS Growth
- ATXS N/A
- REPL N/A
- EPS
- ATXS N/A
- REPL N/A
- Revenue
- ATXS $706,000.00
- REPL N/A
- Revenue This Year
- ATXS N/A
- REPL N/A
- Revenue Next Year
- ATXS N/A
- REPL N/A
- P/E Ratio
- ATXS N/A
- REPL N/A
- Revenue Growth
- ATXS N/A
- REPL N/A
- 52 Week Low
- ATXS $3.56
- REPL $2.68
- 52 Week High
- ATXS $12.72
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- ATXS 67.29
- REPL 62.38
- Support Level
- ATXS $12.31
- REPL $8.50
- Resistance Level
- ATXS $12.62
- REPL $9.30
- Average True Range (ATR)
- ATXS 0.23
- REPL 0.61
- MACD
- ATXS -0.17
- REPL -0.14
- Stochastic Oscillator
- ATXS 72.73
- REPL 75.95
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.